Dilon Technologies forms alliance with Terason Ultrasound in diagnostic imaging
A new study reveals critical molecular mechanisms associated with the development and progression of human neuroblastoma, the most common cancer in young children. The research, published by Cell Press in the January 6th issue of the journal Cancer Cell, may lead to development of future strategies for treatment of this aggressive and unpredictable cancer. Neuroblastoma
Full Post: New insight into critical molecular mechanisms involved in aggressive childhood cancer
Dilon Technologies, Inc., the leader in molecular breast imaging, announced today that they have formed an alliance with Terason Ultrasound to offer an expanded imaging capability when molecular breast imaging and ultrasound may be required.
BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers, particularly for women with high risk factors or that present with questionable mammograms. With BSGI, metabolic activity is assessed and cancerous cells generally display as “hot spots.”
Terason is the innovator and world leader in integrating patented microsystem technology with an Apple MacBook Pro PC. The Terason t3000(TM) Ultrasound System offers premium imaging performance with the portability and functionality of a laptop. When used as a complement to the Dilon 6800 Gamma Camera, physicians are able to move from BSGI to ultrasound without leaving the exam room.
Bob Moussa, President and CEO of Dilon Technologies said, “We are proud to partner with Terason to complement BSGI with ultrasound when appropriate. Through innovative products and partnerships such as this, Dilon continues to expand its offerings to be the best in patient care and cancer detection.”
The Terason t3000 offers best-in-class image quality; ease of use with a dual user interface; and an integrated information management and communications protocol in one system. For quick on-the-spot, accurate scanning in a wide array of clinical applications, transducers quickly connect to the system allowing technicians to perform an ultrasound exam at the point of patient care. Terason’s patented high-density, beam-forming architecture provides a superior performance cost-effective ultrasound solution.
The ultrasound system is built upon an industry respected combination of the Apple PC coupled with Windows Operating System to provide seamless networking capabilities, compatibility with various applications, standard connections, and software updates. The system includes DICOM, Wireless, Integrated CD/DVD, and USB capability. The ergonomically designed slide out dual-user interface is extremely easy to use. The Terason t3000(TM) Ultrasound System is a powerful ultrasound designed to work smarter, enhance workflow, and promote efficiency and diagnostic confidence.
“BSGI has proven to be an important adjunct to mammography and ultrasound in the diagnosis of breast cancer. We are excited to be in a partnership with Dilon as we both continue to offer important advances in care,” said Alice Chiang, Ph.D., Terason’s CEO.
Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC), a difficult to diagnose breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. When compared to mammography, ultrasound and
Full Post: Molecular breast imaging technique shows greater sensitivity over mammography, ultrasound and MRI for difficult to diagnose breast cancer
Breast-Specific Gamma Imaging (BSGI) is shown to be an effective method of identifying mammographically and clinically occult (hidden) breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. According to findings presented today at the annual meeting of the Radiological Society of
Full Post: Breast-specific gamma imaging identifies hidden breast cancer
GE Healthcare continues to re-invent and re-imagine cardiology and the innovations that may help fuel the field through the future. At the 2008 Scientific Sessions of the American Heart Association, in New Orleans this week, the company plans to showcase new products, new relationships and, above all, a new way to look at clinical practice.
Full Post: GE Healthcare showcases new cardiology technology
The world’s first radar breast imaging system developed at Bristol University that could revolutionise the way women are scanned for breast cancer, is being trialled at North Bristol NHS Trust (NBT). Professor Alan Preece and Dr Ian Craddock from the University of Bristol have been working for a number of years to develop a
Full Post: New technology could revolutionse breast cancer screening
Magnetic resonance imaging (MRI) alternated with mammography at six-month intervals can detect breast cancers not identified by mammography alone, a research team from The University of Texas M. D. Anderson Cancer Center will report at the 31st at the CRTC-AACR San Antonio Breast Cancer Symposium. MRI is known to be more sensitive in detecting breast
Full Post: Magnetic resonance imaging alternated with mammography may be best for high-risk women